[HT-05] Hot Topics 05

[HT-05-1] Synuclein-targeting therapies in PD: what do we know and where are we headed?

Takafumi Hasegawa (Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine, Japan)

Dr. Hasegawa received M.D. in 1995 and Ph.D. in 2000 from Tohoku University School of Medicine, Sendai Japan. He joined as Alexander von Humboldt fellow in Hertie-Institute, Tübingen, Germany (Prof. Dr. Philipp Kahle). In 2008, he went back to Japan and currently serves as an associate professor and PI of Parkinson’s Disease (PD) Group in Department of Neurology, Tohoku University School of Medicine. In 2017, he was appointed Associate Professor, in Division of Neurology, Department of Neuroscience & Sensory Organs, Tohoku University Graduate School of Medicine. His research focuses on elucidating the molecular pathogenesis of PD and related disorders leading to the development of disease-modifying therapies. He has made many discoveries, particularly regarding the cell biological mechanisms of prion-like propagation of alpha-synuclein, and the involvement of vesicle trafficking machinery in sporadic and familial PD.